Global Hepatitis C Diagnosis and Treatment Market – Overview
Hepatitis C is the inflammation of liver caused by infection by hepatitis C virus characterized by a host of symptoms such as yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay coloured stools etc. According to the World Health Organisation, hepatitis C affects between 130–150 million people globally every year claiming a toll of 700000 lives. Of those who recover about 15-20% develop liver cirrhosis or liver cancer.
According to Centres for Disease Control & Prevention, in U.S., liver cancer incidence is increasing at a rapid rate (2.3 % per year overall from 2003 – 2012), second only to thyroid cancer. Moreover, the rate of deaths due to liver cancer is increasing faster than for any other type of cancer. Furthermore, Hepatitis B and C are major contributing factors to liver cancer.
According to American Cancer Society, Worldwide, the most common risk factor for liver cancer is chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). These infections lead to cirrhosis of the liver and are responsible for making liver cancer the most common cancer globally.
Get Free Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1569
The market for hepatitis C diagnosis & treatment is driven by factors such as increasing prevalence of liver cancer, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations, drug abuse and unsafe sex etc. On the other hand, the market constraining factors are self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies such as between Gilead and Merck, rising urbanization and better sanitation etc.
Key Players:
- Vertex Pharmaceuticals Incorporated,
- Gilead Sciences Inc,
- Bristol-Myers Squibb,
- Novartis AG,
- Abbvie Inc,
- GlaxoSmithKline plc,
- Johnson & Johnson,
- BMS,
- Hoffmann-La Roche Ltd, and
- Merck & Co., Inc
are among the leading competitors included in the reports competitive analysis which includes market shares of each competitor and the various growth strategies they employ.
Latest Industry News:
October, 2013 – Janssen (Parent organisation Johnson & Johnson Services, Inc.) acquired investigational NS5A Inhibitor for the treatment of Hepatitis C from GlaxoSmithKline. According to company reports, GSK2336805 is an investigational NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis.
October, 2013 – Bristol-Myers Squibb to presented range of new Hepatitis C data at the 2013 American Association for the Study of Liver Diseases (AASLD). According to company reports, Bristol-Myers Squibb’s hepatitis C includes compounds with different mechanisms of action, biologics as well as small molecule direct-acting antivirals. These compounds were being studied as part of multiple treatment regimens with the goal of increasing SVR rates across different patient types.
Segments:
MRFR’s analysis of the market segments it on the basis of diagnostic tests, and region. Diagnostic tests used to determine Hepatitis C Diagnosis and Treatment in a patient includes chemiluminescence immunoassay (CIA), enzyme immunoassay(EIA), point-of-care rapid immunoassay, recombinant immunoblot assay (RIBA), and others.
Regions that have been covered in the report span global geography and include four key regions, namely the Americas, Asia Pacific, Europe, and the Middle East and Africa.
Regional Analysis:
The Americas due to their inclusion of the US have achieved a leadership role in the global Hepatitis C Diagnosis and Treatment market with European region following closely. These regions have drug use statistics and a popular tattoo culture which contribute to the cases of Hepatitis C Diagnosis and Treatment. Moreover, the presence of well-developed healthcare sectors which significant investments and the presence of stringent government standards concerning needle sterility in hospitals are expected to impact these markets.
Meanwhile, the Asia Pacific is growing at a rapid rate. The regions healthcare segment is growing and improving significantly. However, various underdeveloped parts of the region have high cases of Hepatitis C Diagnosis and Treatment which impact the market substantially. Moreover, countries such as India and China are growing at the most rapid rate due to the high demand for efficient healthcare, the presence of untapped potential and rapidly reforming healthcare sectors.
The MEA region is likely to witness sluggish growth despite a significant presence of Hepatitis C Diagnosis and Treatment due to unsanitary health practices in underdeveloped regions of the MEA region.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/hepatitis-c-diagnosis-treatment-market-1569
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/hepatitis-c-diagnosis-treatment-market-1569